{"disease":{"id":"advanced-gastric-cancer","name":"advanced gastric cancer"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Unresectable, advanced or recurrent gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":79,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07401199","title":"Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Qun Zhao","has_results":false},{"nct_id":"NCT06979817","title":"Machine Learning Model Guided by TLS Predicts Survival and Immune Features in Gastric Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Qun Zhao","has_results":false},{"nct_id":"NCT07144995","title":"MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1143,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03223376","title":"A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":703,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":false},{"nct_id":"NCT06716593","title":"Trajectory of Body Composition Identifies LAGC with Cachexia Following NACT","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Chang-Ming Huang, Prof.","has_results":false},{"nct_id":"NCT06235164","title":"The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":585,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT03504397","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT03961373","title":"Standard Versus Super-extended Lymphadenectomy After Neo-adjuvant Chemotherapy for Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":539,"lead_sponsor_name":"University of Siena","has_results":false},{"nct_id":"NCT03653507","title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":507,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06901531","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT06727981","title":"First-Line and Neoadjuvant Immunotherapy for Gastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT06177041","title":"M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":486,"lead_sponsor_name":"FutureGen Biopharmaceutical (Beijing) Co., Ltd","has_results":false},{"nct_id":"NCT06597227","title":"Proximal Gastrectomy Vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":404,"lead_sponsor_name":"Guihua Wang","has_results":false},{"nct_id":"NCT07259226","title":"Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT06902545","title":"A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.","phase":"","overall_status":"RECRUITING","enrollment_count":377,"lead_sponsor_name":"Astellas Pharma Korea, Inc.","has_results":false},{"nct_id":"NCT06123494","title":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06947291","title":"Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT06881043","title":"The Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT06478394","title":"Machine Learning-driven Noninvasive Screening of Transcriptomics Liquid Biopsies for Early Diagnosis of Occult Peritoneal Metastases in Locally Advanced Gastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Qun Zhao","has_results":false},{"nct_id":"NCT06767436","title":"A Multi-center Real-world Efficacy and Safety of Trastuzumab-deruxtecan in Advanced Gastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT05993234","title":"A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","phase":"","overall_status":"RECRUITING","enrollment_count":257,"lead_sponsor_name":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","has_results":false},{"nct_id":"NCT06376773","title":"Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.","phase":"","overall_status":"COMPLETED","enrollment_count":234,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT06277453","title":"Effect of Adjuvant Chemotherapy Cycles on Patients With Node-negative Gastric Cancer Following Neoadjuvant Chemotherapy","phase":"","overall_status":"UNKNOWN","enrollment_count":219,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT05610332","title":"Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":216,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT05524974","title":"Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":203,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT06459921","title":"Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT02935634","title":"A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":190,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT03564834","title":"Laparoscopic Versus Open Gastrectomy for Elderly Local Advanced Gastric Cancer Patients","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06271837","title":"A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":175,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06157892","title":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT06769425","title":"HS-10502 Combination Treatment in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":157,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03045770","title":"mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT06169410","title":"Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":140,"lead_sponsor_name":"Yang Jianjun, PhD","has_results":false},{"nct_id":"NCT03427814","title":"Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT04492488","title":"A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":129,"lead_sponsor_name":"Shanghai Miracogen Inc.","has_results":false},{"nct_id":"NCT06346093","title":"Fecal Microbiota Transplantation (FMT) in Patients With Advanced Gastric Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT02952729","title":"Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Mersana Therapeutics","has_results":false},{"nct_id":"NCT03350477","title":"Bioinformation Therapy for Gastric Cancer","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Fuda Cancer Hospital, Guangzhou","has_results":false},{"nct_id":"NCT04189445","title":"Futibatinib in Patients With Specific FGFR Aberrations","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":115,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":true},{"nct_id":"NCT04195828","title":"Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT05348161","title":"Dynamic Multiomics Evaluation of Anti-HER2 and Immunotherapy in HER2 Positive Gastric Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT05149807","title":"Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":81,"lead_sponsor_name":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT06767449","title":"Zolbetuximab Claudin18.2 Positive, HER2 Negative, Advanced Gastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT07294664","title":"PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"The First Affiliated Hospital of Zhengzhou University","has_results":false},{"nct_id":"NCT03030937","title":"Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":74,"lead_sponsor_name":"Fujian Cancer Hospital","has_results":false},{"nct_id":"NCT07537348","title":"Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":73,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT04792515","title":"Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":67,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT06592287","title":"The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":66,"lead_sponsor_name":"Xianglin Yuan","has_results":false},{"nct_id":"NCT01602406","title":"Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05188209","title":"A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Shanghai Miracogen Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}